Status:
RECRUITING
Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction
Lead Sponsor:
Peking University People's Hospital
Conditions:
Acute Leukemia
MDS
Eligibility:
All Genders
Brief Summary
A research investigation into the efficacy of digital Polymerase Chain Reaction (dPCR) for monitoring measurable residual disease (MRD) during allogeneic hematopoietic stem cell transplantation, with ...
Detailed Description
This prospective clinical study focuses on patients diagnosed with leukemia, myelodysplastic syndromes (MDS), and related hematological conditions post-allogeneic hematopoietic stem cell transplantati...
Eligibility Criteria
Inclusion
- The presence of at least one fusion gene or hematological tumor-associated mutation detected at diagnosis by NGS or real-time PCR provided for posttransplant MRD monitoring.
- Neutrophil engraftment
- Received at least one MRD monitoring by digital PCR after HSCT
Exclusion
- Patients who relapsed or died before the first digital PCR monitoring
- Patients only with mutations in DNMT3A, TET2, and ASXL1 ("DTA mutations") or only germline mutations
Key Trial Info
Start Date :
January 8 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06211166
Start Date
January 8 2024
End Date
December 31 2027
Last Update
January 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044